

AMENDMENTS

In the Claims:

Please replace present claim 13 with the following claim 13:

Sub
DI
ET

13. (Amended) A method to elicit an antitumor immune response to prostate tumors in a subject, which method comprises
administering to said subject at least one active ingredient formulated for administration to said subject,
wherein said active ingredient comprises or expresses at least one antigen over-represented in the prostate gland,
wherein said active ingredient is human prostate-specific membrane antigen (PSMA); or prostatic acid phosphatase (PAP); or mixtures of the foregoing; or
is a nucleic acid that generates said antigen or antigens *in situ*.

Please cancel claims 14 and 17.